These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

240 related items for PubMed ID: 2167930

  • 1. Virus neutralizing activity induced by synthetic peptides of glycoprotein D of herpes simplex virus type 1, selected by their reactivity with hyperimmune sera from mice.
    Geerligs HJ, Kocken CH, Drijfhout JW, Weijer WJ, Bloemhoff W, Wilterdink JB, Welling GW, Welling-Wester S.
    J Gen Virol; 1990 Aug; 71 ( Pt 8)():1767-74. PubMed ID: 2167930
    [Abstract] [Full Text] [Related]

  • 2. Antibodies against synthetic peptides of herpes simplex virus type 1 glycoprotein D and their capability to neutralize viral infectivity in vitro.
    Weijer WJ, Drijfhout JW, Geerligs HJ, Bloemhoff W, Feijlbrief M, Bos CA, Hoogerhout P, Kerling KE, Popken-Boer T, Slopsema K.
    J Virol; 1988 Feb; 62(2):501-10. PubMed ID: 2826811
    [Abstract] [Full Text] [Related]

  • 3. The gH-gL complex of herpes simplex virus (HSV) stimulates neutralizing antibody and protects mice against HSV type 1 challenge.
    Peng T, Ponce-de-Leon M, Jiang H, Dubin G, Lubinski JM, Eisenberg RJ, Cohen GH.
    J Virol; 1998 Jan; 72(1):65-72. PubMed ID: 9420201
    [Abstract] [Full Text] [Related]

  • 4. Escherichia coli-derived envelope protein gD but not gC antigens of herpes simplex virus protect mice against a lethal challenge with HSV-1 and HSV-2.
    Bröker M, Abel KJ, Köhler R, Hilfenhaus J, Amann E.
    Med Microbiol Immunol; 1990 Jan; 179(3):145-59. PubMed ID: 2169577
    [Abstract] [Full Text] [Related]

  • 5. Reactivity of human sera with overlapping synthetic peptides of herpes simplex virus type 1 glycoprotein D.
    Geerligs HJ, Feijlbrief M, Bolk M, Bos CA, Drijfhout JW, Welling GW, Welling-Wester S.
    Arch Virol; 1990 Jan; 114(3-4):251-8. PubMed ID: 2173527
    [Abstract] [Full Text] [Related]

  • 6. Synthetic glycoprotein D-related peptides protect mice against herpes simplex virus challenge.
    Eisenberg RJ, Cerini CP, Heilman CJ, Joseph AD, Dietzschold B, Golub E, Long D, Ponce de Leon M, Cohen GH.
    J Virol; 1985 Dec; 56(3):1014-7. PubMed ID: 2999419
    [Abstract] [Full Text] [Related]

  • 7. Epitope mapping of the 273-284 region of HSV glycoprotein D by synthetic branched polypeptide carrier conjugates.
    Hudecz F, Hilbert A, Mezö G, Mucsi I, Kajtár J, Bösze S, Kurucz I, Rajnavölgyi E.
    Pept Res; 1993 Dec; 6(5):263-71. PubMed ID: 7504960
    [Abstract] [Full Text] [Related]

  • 8. Adjuvant-independent enhanced immune responses to recombinant herpes simplex virus type 1 glycoprotein D by fusion with biologically active interleukin-2.
    Hazama M, Mayumi-Aono A, Asakawa N, Kuroda S, Hinuma S, Fujisawa Y.
    Vaccine; 1993 Dec; 11(6):629-36. PubMed ID: 8391739
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Immunological properties of an N-terminal fragment of herpes simplex virus type 1 glycoprotein D expressed in Escherichia coli.
    Kocken CH, Geerligs HJ, Bos CA, Ab G, Weijer WJ, Drijfhout JW, Welling GW, Welling-Wester S.
    Arch Virol; 1988 Dec; 103(3-4):267-74. PubMed ID: 2850785
    [Abstract] [Full Text] [Related]

  • 11. Immunological properties of multiple repeats of a linear epitope of herpes simplex virus type 1 glycoprotein D.
    Van der Ploeg JR, Drijfhout JW, Feijlbrief M, Bloemhoff W, Welling GW, Welling-Wester S.
    J Immunol Methods; 1989 Nov 30; 124(2):211-7. PubMed ID: 2480978
    [Abstract] [Full Text] [Related]

  • 12. Immunization with a vaccinia virus recombinant expressing herpes simplex virus type 1 glycoprotein D: long-term protection and effect of revaccination.
    Rooney JF, Wohlenberg C, Cremer KJ, Moss B, Notkins AL.
    J Virol; 1988 May 30; 62(5):1530-4. PubMed ID: 2833606
    [Abstract] [Full Text] [Related]

  • 13. Purification of herpes simplex virus glycoproteins B and C using monoclonal antibodies and their ability to protect mice against lethal challenge.
    Roberts PL, Duncan BE, Raybould TJ, Watson DH.
    J Gen Virol; 1985 May 30; 66 ( Pt 5)():1073-85. PubMed ID: 2582080
    [Abstract] [Full Text] [Related]

  • 14. Passive transfer of anti-herpes simplex virus type 2 monoclonal and polyclonal antibodies protect against herpes simplex virus type 1-induced but not herpes simplex virus type 2-induced stromal keratitis.
    Ritchie MH, Oakes JE, Lausch RN.
    Invest Ophthalmol Vis Sci; 1993 Jul 30; 34(8):2460-8. PubMed ID: 8392037
    [Abstract] [Full Text] [Related]

  • 15. Use of synthetic peptides to map the antigenic determinants of glycoprotein D of herpes simplex virus.
    Strynadka NC, Redmond MJ, Parker JM, Scraba DG, Hodges RS.
    J Virol; 1988 Sep 30; 62(9):3474-83. PubMed ID: 2457115
    [Abstract] [Full Text] [Related]

  • 16. Efficacy of recombinant herpes simplex virus 1 glycoprotein D candidate vaccines in mice.
    Durmanová V, Mosko T, Sapák M, Kosovský J, Rezuchová I, Buc M, Rajcáni J.
    Acta Microbiol Immunol Hung; 2006 Dec 30; 53(4):459-77. PubMed ID: 17278713
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Induction of protective immunity with antibody to herpes simplex virus type 1 glycoprotein H (gH) and analysis of the immune response to gH expressed in recombinant vaccinia virus.
    Forrester AJ, Sullivan V, Simmons A, Blacklaws BA, Smith GL, Nash AA, Minson AC.
    J Gen Virol; 1991 Feb 30; 72 ( Pt 2)():369-75. PubMed ID: 1704412
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.